AGC Biologics will produce chronic gout treatment for Horizon Therapeutics

Prospectively, AGC Biologics' Danish unit will help produce the gout treatment Krystexxa for Horizon Therapeutics.
Photo: Colourbox
Photo: Colourbox

Contract development and manufacturing organization (CDMO) AGC Biologics will be producing the drug Krystexxa against chronic gout for US firm Horizon Therapeutics in the future. Production will take place in AGC Biolotics' Danish facilities, the contractor informs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading